deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT04353102

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies

Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Conditions Advanced Solid Malignancies
Interventions YH002
Updated 9 times since 2020 Last updated: Jul 21, 2022 Started: Apr 22, 2020 Primary completion: Sep 14, 2021 Completion: Nov 24, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Malignancies and is currently completed. Eucure (Beijing) Biopharma Co., Ltd leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2020 – ~Jan 2021 · 8 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2021 – ~May 2021 · 3 months · monthly snapshotRecruiting~May 2021 – ~Jun 2021 · 31 days · monthly snapshotRecruiting~Jun 2021 – ~Jul 2022 · 13 months · monthly snapshotRecruiting~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshotCompleted~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  5. Jun 2021 — Jul 2022 [monthly]

    Recruiting PHASE1

▶ Show 4 earlier versions

  1. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  2. Feb 2021 — May 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE1

  4. May 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eucure (Beijing) Biopharma Co., Ltd
Data source: Eucure (Beijing) Biopharma Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations